<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00355095</url>
  </required_header>
  <id_info>
    <org_study_id>0026</org_study_id>
    <nct_id>NCT00355095</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis</brief_title>
  <official_title>Double Blind, Placebo-controlled Study to Determine the Safety and Efficacy of Erythropoietin as an add-on Therapy of Methylprednisolone in Subjects With Acute Optic Neuritis (VISION PROTECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of erythropoietin as an&#xD;
      add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SUMMARY This study is a multicenter, double-blind, placebo-controlled, parallel-group study&#xD;
      to determine the safety and efficacy of erythropoietin (Epo) as an add-on therapy to&#xD;
      methylprednisolone (Mpred) in subjects with acute autoimmune optic neuritis.&#xD;
&#xD;
      The primary study endpoint is nerve fiber loss in the optical nerve head determined by&#xD;
      optical coherence tomography at weeks 4, 8, and 16 compared to baseline.&#xD;
&#xD;
      Further study objectives include visual acuity, visual field perception, optic nerve atrophy&#xD;
      determined by magnetic resonance imaging (MRI), and recovery of visual evoked potentials&#xD;
      (VEPs).&#xD;
&#xD;
      A number of 40 subjects will be randomized in equal numbers into one of the two treatment&#xD;
      groups.&#xD;
&#xD;
      Treatment groups:&#xD;
&#xD;
      Epo or placebo will be administered i.v. at three consecutive days. Epo or placebo is to be&#xD;
      given once daily following application of Mpred preferably between 8 and 10 a.m..&#xD;
&#xD;
      Subjects will be randomized to one of the following two treatment groups and dosed as&#xD;
      follows:&#xD;
&#xD;
        -  Mpred at a dose of 1000 mg per day on days 1 - 3 given as an i.v. infusion AND 3.3 x&#xD;
           10^4 IU recombinant human Epo per day on days 1- 3 given as an i.v. bolus injection.&#xD;
&#xD;
        -  Mpred at a dose of 1000 mg per day on days 1 - 3 given as an i.v. infusion AND placebo&#xD;
           (normal saline) on days 1 - 3 given as an i.v. bolus injection.&#xD;
&#xD;
      Men and women between the ages of 18 and 50, inclusive, diagnosed with acute unilateral optic&#xD;
      neuritis with or without prior diagnosis of multiple sclerosis (according to McDonald&#xD;
      criteria; Polman et al., 2005) will be considered for inclusion into the study. Those&#xD;
      subjects must have a decreased visual acuity on the affected eye to 0.5 or less and must have&#xD;
      signed written informed consent. While safety will be monitored during the study, an efficacy&#xD;
      evaluation will be done after all subjects have completed week 16.&#xD;
&#xD;
      Each subject included in the study will be seen by a treating neurologist and an examining&#xD;
      neurologist as well as by an examining ophthalmologist. The treating neurologist will&#xD;
      function as the primary treating physician and conduct all subject safety assessments. The&#xD;
      examining ophthalmologist and the examining neurologist will conduct all evaluations of&#xD;
      vision/optical nerve head atrophy and neurological symptoms, respectively, but will not be&#xD;
      involved in any other aspect of patient care. A neurophysiologist will perform measurements&#xD;
      of VEPs. MRIs will be performed by a neuroradiologist.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>nerve fiber loss in the optical nerve head determined by optical coherence tomography at weeks 4,8 and 16 compared to baseline. Measurements at baseline and week 16 are used to calculate estimates for changes and differences between the groups.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity and visual field perception determined at weeks 1, 4, 8, 16 compared to baseline (week 0). MRI measurements of optic nerve atrophy performed at weeks 4, 8 and 16 compared to baseline (week 0)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Optic Neuritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>erythropoietin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>intravenous daily 3.3 *10^4 Units, duration 3 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ErypoÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible to participate in this study, candidates must meet the following eligibility&#xD;
        criteria at the time of randomization:&#xD;
&#xD;
          -  Must give written informed consent and authorize the release and use of protected&#xD;
             health information (PHI).&#xD;
&#xD;
          -  Must be 18 to 50 years old, inclusive, at the time of informed consent.&#xD;
&#xD;
          -  Must have acute unilateral optic neuritis with or without prior diagnosis of MS&#xD;
             (according to McDonald criteria).&#xD;
&#xD;
          -  Symptoms related to optic neuritis must exist for no longer than 10 days prior to&#xD;
             inclusion.&#xD;
&#xD;
          -  Must have had normal visual acuity on both eyes before and no history of optic&#xD;
             neuritis.&#xD;
&#xD;
          -  Must have a decreased visual acuity on the affected eye to 0.5 or less at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Candidates will be excluded from study if any of the following exclusion criteria exist at&#xD;
        the time of randomization:&#xD;
&#xD;
        Medical history:&#xD;
&#xD;
          -  Abnormal laboratory results or clinical signs indicative of any significant cardiac,&#xD;
             endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,&#xD;
             gastrointestinal, dermatologic, psychiatric, renal, neurological (other than MS),&#xD;
             and/or other major disease.&#xD;
&#xD;
          -  History of prior optic neuritis on the affected or non-affected eye.&#xD;
&#xD;
          -  History of squint or amblyopia on either side.&#xD;
&#xD;
          -  Hyperopia &gt; 3dptr on either side.&#xD;
&#xD;
          -  Myopia &lt; -5dptr on either side.&#xD;
&#xD;
          -  Astigmatism &gt; 2dptr on either side.&#xD;
&#xD;
          -  Horizontal cup disc ratio &gt; 0.5 on either side.&#xD;
&#xD;
          -  Retinal nerve fiber layer thickness outside normal values (with respect to the OCT&#xD;
             data base).&#xD;
&#xD;
          -  Ocular diseases effecting visual acuity or visual fields (cataract, glaucoma,&#xD;
             maculadegeneration, diabetic retinopathy, retinal heredodegeneration or others).&#xD;
&#xD;
          -  History of elevated blood pressure.&#xD;
&#xD;
          -  Systolic blood pressure of &gt; 159 mmHg, diastolic blood pressure &gt; 99 mmHg at screening&#xD;
             examination.&#xD;
&#xD;
          -  History of thromboembolic events.&#xD;
&#xD;
          -  Frequent thromboembolic events in 1st grade family members.&#xD;
&#xD;
          -  Significant surgery within the 4 weeks prior to randomization.&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions after administration of Epo.&#xD;
&#xD;
          -  History of malignancy.&#xD;
&#xD;
          -  History of seizures.&#xD;
&#xD;
          -  Tuberculosis with ongoing or unknown activity.&#xD;
&#xD;
          -  Acute gastrointestinal ulceration within the last three months.&#xD;
&#xD;
          -  Acute virus, bacterial or fungus infection.&#xD;
&#xD;
          -  Infection with HIV, HBV, or HCV.&#xD;
&#xD;
          -  History of colitis ulcerosa, diverticulitis, or acute enteroanastomosis.&#xD;
&#xD;
          -  Severe osteoporosis.&#xD;
&#xD;
          -  Active immunization within 2 weeks prior to inclusion.&#xD;
&#xD;
          -  Diagnosis of phenylketonuria.&#xD;
&#xD;
          -  Implanted cardiac pacemaker or other non MRI-compatible metallic body implants.&#xD;
&#xD;
          -  History of drug or alcohol abuse (as defined by the investigator) within 2 years prior&#xD;
             to randomization.&#xD;
&#xD;
          -  Any of the following abnormal blood tests at screening: alanine transaminase/serum&#xD;
             glutamate-pyruvate transaminase (AST/SGPT), or aspartate transaminase/serum&#xD;
             glutamicoxaloacetic transaminase (AST/SGOT), gamma-glutamyl-transferase (GGT), or&#xD;
             serum creatinine &gt; 2 times the upper limit of normal; hematocrit &gt; the upper limit of&#xD;
             normal.&#xD;
&#xD;
        Treatment history&#xD;
&#xD;
          -  Prior treatment with cyclosporine, mitoxantrone, methotrexate, cyclophosphamide or&#xD;
             other immunosuppressive agents.&#xD;
&#xD;
          -  Treatment with corticosteroids or Epo within 30 days prior to randomization.&#xD;
             Miscellaneous&#xD;
&#xD;
          -  Female subjects considering becoming pregnant while in the study.&#xD;
&#xD;
          -  Female subjects who are currently pregnant or breast-feeding.&#xD;
&#xD;
          -  Previous participation in this study or any other investigational drug study within&#xD;
             the last four weeks.&#xD;
&#xD;
          -  Current enrollment in any other investigational drug study.&#xD;
&#xD;
          -  Unwillingness or inability to comply with the requirements of the protocol including&#xD;
             the presence of any condition (physical, mental, or social) that is likely to affect&#xD;
             the subject's ability to comply with the protocol.&#xD;
&#xD;
          -  Any other reasons that, in the opinion of the investigator, the subject is determined&#xD;
             to be unsuitable for enrollment in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricarda Diem, MD Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Neurology University Homborg Hospital of the Saarland, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology University Hospital Goettingen</name>
      <address>
        <city>Goettingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology University Homborg Hospital of the Saarland, Germany</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Hamburg-Eppendorf (Institut of Neuroimmunology and Clinical MS Research (INIMS))</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Maier K, Rau CR, Storch MK, SÃ¤ttler MB, Demmer I, Weissert R, Taheri N, Kuhnert AV, BÃ¤hr M, Diem R. Ciliary neurotrophic factor protects retinal ganglion cells from secondary cell death during acute autoimmune optic neuritis in rats. Brain Pathol. 2004 Oct;14(4):378-87.</citation>
    <PMID>15605985</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>July 20, 2006</study_first_submitted>
  <study_first_submitted_qc>July 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2006</study_first_posted>
  <last_update_submitted>September 12, 2012</last_update_submitted>
  <last_update_submitted_qc>September 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dirk Simon</name_title>
    <organization>Institut fuer anwendungsorientierte Forschung und klinische Studien gGmbH</organization>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>add-on Therapy</keyword>
  <keyword>erythropoietin</keyword>
  <keyword>methylprednisolone</keyword>
  <keyword>autoimmune optic neuritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

